Memantine
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| |
| Image:Memantine-3d-sticks.png | |
| Memantine
| |
| Systematic (IUPAC) name | |
| 1-amino-3,5-dimethyl-adamantane | |
| Identifiers | |
| CAS number | |
| ATC code | N06 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C12H21N |
| Mol. mass | 179.3 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ~100% |
| Metabolism | Hepatic (<10%) |
| Half life | 60–100 hours |
| Excretion | Renal |
| Therapeutic considerations | |
| Licence data |
, |
| Pregnancy cat. | |
| Legal status |
S4 (Au), POM (UK), ℞-only (U.S.) |
| Routes | Oral |
Memantine is the first in a novel class of Alzheimer's disease medications acting on the glutamatergic system. Memantine was developed by Merz and licensed to Forest for the U.S. and Lundbeck for selected European and international markets. Memantine is marketed under the brands Axura® and Akatinol® by Merz, Namenda® by Forest and Ebixa® by Lundbeck.
Pharmacology
Glutamatergic (NMDA receptor)
A dysfunction of glutamatergic neurotransmission, manifested as neuronal excitotoxicity, is hypothesized to be involved in the etiology of Alzheimer's disease. Targeting the glutamatergic system, specifically NMDA receptors, offers a novel approach to treatment in view of the limited efficacy of existing drugs targeting the cholinergic system.[1]
Memantine is a low-affinity voltage-dependent uncompetitive antagonist at glutamatergic NMDA receptors. [1] [1] By binding to the NMDA receptor with a higher affinity than Mg2+ ions, memantine is able to inhibit the prolonged influx of Ca2+ ions which forms the basis of neuronal excitotoxicity. The low affinity and rapid kinetics of memantine at the level of the NMDA receptor-channel, however, preserves the physiological function of the receptor as it can still be activated by the relatively high concentrations of glutamate released following depolarization of the presynaptic neuron. [1] Whether the interaction of memantine with NMDA receptors plays a role in the symptomatic improvement the drug produces in Alzheimer's disease is a matter of speculation. Moreover, there is no evidence as yet that the ability of memantine to protect against NMDA receptor-mediated excitotoxicity has a disease modifying effect in Alzheimer's.
Serotonergic (5-HT3 receptor)
Memantine acts as an uncompetitive antagonist at the 5HT3 receptor, with a potency similar to that for the NMDA receptor.[1] The clinical significance of this serotonergic activity in the treatment of Alzheimer's disease is unknown.
Cholinergic (Nicotinic acetylcholine receptor)
Memantine acts as an uncompetetive antagonist at different neuronal nicotinic neuronal receptors (nAChRs) at potencies similar to the NMDA receptor.[1][1] It has been shown that the number of nicotinic receptors in the brain are reduced in Alzheimer's disease, even in the absence of a general decrease in the number of neurons, and nicotinic receptor agonists are viewed as interesting targets for anti-Alzheimer drugs.[1]
Clinical use
Indications
Although memantine is approved for treatment of moderate to severe Alzheimer's Disease[1] its usage has been recommended against by the UK's National Institute for Clinical Excellence.[1]
Memantine has been associated with a moderate decrease in clinical deterioration in Alzheimer's disease.[1] A systematic review of randomised controlled trials found that memantine has a small positive effect on cognition, mood, behaviour, and the ability to perform daily activities in moderate to severe Alzheimer's disease, but an unknown effect in mild to moderate disease.[1]
Memantine is also being tested for Opioid dependence, systemic lupus erythematosus, depression, obsessive compulsive disorder, glaucoma, tinnitus, neuropathic pain, and pervasive developmental disorders.
Adverse drug reactions
Memantine is generally well-tolerated.[1] Common adverse drug reactions (≥1% of patients) include: confusion, dizziness, drowsiness, headache, insomnia, agitation, and/or hallucinations. Less common adverse effects include: vomiting, anxiety, hypertonia, cystitis, and increased libido.[1][1]
See also
References
External links
- Lipton SA (2005). "The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism". Current Alzheimer research 2 (2): 155-65. PMID 15974913.
Psychoanaleptics: anti-dementia drugs (N06D) | |
|---|---|
| Anticholinesterases | Tacrine - Donepezil - Rivastigmine - Galantamine |
| Other | NMDA receptor antagonist (Memantine) - Ginkgo biloba |
Dissociative hallucinogens | |
|---|---|
| Kappa agonists | Cyclazocine - Enadoline - Salvinorin A - Pentazocine - Tifluadom |
| NMDA receptor antagonists | 2-MDP - Dexoxadrol - Dextromethorphan - Dizocilpine - Esketamine - Etoxadrol - Ketamine - PCE - PCP - PCPy - TCP - Tiletamine |
| Others | Efavirenz - Muscimol - Nitrous oxide - Xenon |
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
